Want to see IDXGD full AI Analyst Report?
IDXGD Stock Chart & Stats
$1.46
$0.08(5.79%)
At close: 4:00 PM EDT
$1.46
$0.08(5.79%)
Day’s Range― - ―
52-Week Range$3.85 - $12.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)11.58K
Market Cap
$200.83M
Enterprise Value$43.46
Total Cash (Recent Filing)$2.69M
Total Debt (Recent Filing)$974.00K
Price to Earnings (P/E)<0.1
Beta1.66
Next Earnings
Nov 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.38
Shares Outstanding27,700,905
10 Day Avg. Volume15,402
30 Day Avg. Volume11,583
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.24
Price to Sales (P/S)0.14
P/FCF Ratio0.99
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved ProfitabilityThe shift to sustained operating profitability provides a stronger base for funding laboratory operations and product development. If maintained, improved earnings can support financial resilience, although the quality and durability of those earnings still require monitoring.
Stronger Balance SheetPositive equity and minimal leverage reduce solvency risk and give Interpace greater flexibility to manage reimbursement pressure, invest in diagnostic offerings, and absorb operating volatility. This represents a meaningful improvement from the negative-equity periods reported in 2021–2024.
Positive Current Cash GenerationPositive operating and free cash flow indicate that the laboratory business is currently converting operations into liquidity, supporting ongoing needs without relying as heavily on external financing. Cash flow close to net income also offers a constructive quality signal.
Bears Say
Declining Revenue BaseA shrinking revenue base can weaken operating leverage, limit investment capacity, and signal pressure on test volumes, reimbursement, or customer adoption. Sustained contraction would make recent profitability harder to preserve and reduce visibility into the company’s durable growth profile.
Weaker Cash ConversionAlthough cash generation is currently positive, weakening TTM momentum and operating cash flow below net income indicate that reported earnings are not translating into cash as strongly as before. Persistent deterioration could constrain reinvestment and increase dependence on working-capital improvements.
Earnings Quality UncertaintyThe combination of falling revenue, unusually high margins, and historically volatile equity suggests current profitability may not fully represent recurring diagnostic operations. If non-core or one-time effects fade, earnings could normalize materially and reduce confidence in the reported run-rate.
IDXGD FAQ
What was Interpace Diagnostics Group’s price range in the past 12 months?
Interpace Diagnostics Group lowest stock price was $3.85 and its highest was $12.00 in the past 12 months.
What is Interpace Diagnostics Group’s market cap?
Interpace Diagnostics Group’s market cap is $200.83M.
When is Interpace Diagnostics Group’s upcoming earnings report date?
Interpace Diagnostics Group’s upcoming earnings report date is Nov 11, 2026 which is in 75 days.
How were Interpace Diagnostics Group’s earnings last quarter?
Interpace Diagnostics Group released its earnings results on Aug 10, 2026. The company reported $0.006 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Interpace Diagnostics Group overvalued?
According to Wall Street analysts Interpace Diagnostics Group’s price is currently Overvalued.
Does Interpace Diagnostics Group pay dividends?
Interpace Diagnostics Group does not currently pay dividends.
What is Interpace Diagnostics Group’s EPS estimate?
Interpace Diagnostics Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Interpace Diagnostics Group have?
Interpace Diagnostics Group has 27,700,905 shares outstanding.
What happened to Interpace Diagnostics Group’s price movement after its last earnings report?
Interpace Diagnostics Group reported an EPS of $0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.824%.
Which hedge fund is a major shareholder of Interpace Diagnostics Group?
Currently, no hedge funds are holding shares in IDXGD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Interpace Diagnostics Group
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodules for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.